TY - JOUR
T1 - Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS)
T2 - Is There Enough Evidence?
AU - Madigan, Margaret A.
AU - Gupta, Ashim
AU - Bowirrat, Abdalla
AU - Baron, David
AU - Badgaiyan, Rajendra D.
AU - Elman, Igor
AU - Dennen, Catherine A.
AU - Braverman, Eric R.
AU - Gold, Mark S.
AU - Blum, Kenneth
N1 - Funding Information:
R.D.B. is the recipient of NIH R01NS073884, and K.B. and Marjorie Gondre-Lewis. (Howard University) are recipients of R41 MD012318/MD/NIMHD NIH HHS/United States.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - This brief commentary aims to provide an overview of the available and relatively new precision management of reward deficiencies manifested as substance and behavioral disorders. Current and future advances, concepts, and the substantial evidential basis of this potential therapeutic and prophylactic treatment modality are presented. Precision Behavioral Management (PBM), conceptualized initially as Precision Addiction Management (PAM), certainly deserves consideration as an important modality for the treatment of impaired cognitive control in reward processing as manifested in people with neurobiologically expressed Reward Deficiency Syndrome (RDS).
AB - This brief commentary aims to provide an overview of the available and relatively new precision management of reward deficiencies manifested as substance and behavioral disorders. Current and future advances, concepts, and the substantial evidential basis of this potential therapeutic and prophylactic treatment modality are presented. Precision Behavioral Management (PBM), conceptualized initially as Precision Addiction Management (PAM), certainly deserves consideration as an important modality for the treatment of impaired cognitive control in reward processing as manifested in people with neurobiologically expressed Reward Deficiency Syndrome (RDS).
KW - Genetic Addiction Risk Severity (GARS) test
KW - Restoregen ®
KW - dopamine
KW - hypodopaminergia
KW - pro-dopamine regulation (KB220)
UR - http://www.scopus.com/inward/record.url?scp=85130793578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130793578&partnerID=8YFLogxK
U2 - 10.3390/ijerph19116395
DO - 10.3390/ijerph19116395
M3 - Comment/debate
C2 - 35681980
AN - SCOPUS:85130793578
SN - 1661-7827
VL - 19
JO - International Journal of Environmental Research and Public Health
JF - International Journal of Environmental Research and Public Health
IS - 11
M1 - 6395
ER -